

KRAS Conjugated Antibody

Catalog No: #C27759



Package Size: #C27759-AF350 100ul #C27759-AF405 100ul #C27759-AF488 100ul
 #C27759-AF555 100ul #C27759-AF594 100ul #C27759-AF647 100ul
 #C27759-AF680 100ul #C27759-AF750 100ul #C27759-Biotin 100ul

Orders: order@signalwayantibody.com
 Support: tech@signalwayantibody.com

Description

Product Name	KRAS Conjugated Antibody
Host Species	Rabbit
Clonality	Polyclonal
Isotype	IgG
Purification	Affinity purification
Applications	most applications
Species Reactivity	Ms,Rt
Immunogen Description	Recombinant fusion protein of human KRAS (NP_004976.2).
Conjugates	Biotin AF350 AF405 AF488 AF555 AF594 AF647 AF680 AF750
Other Names	KRAS; C-K-RAS; CFC2; K-RAS2A; K-RAS2B; K-RAS4A; K-RAS4B; KI-RAS; KRAS1; KRAS2; NS; NS3; RALD; RASK2; c-Ki-ras2; GTPase KRas
Accession No.	Swiss-Prot#:P01116NCBI Gene ID:3845
Uniprot	P01116
GeneID	3845;
Excitation Emission	AF350: 346nm/442nm AF405: 401nm/421nm AF488: 493nm/519nm AF555: 555nm/565nm AF594: 591nm/614nm AF647: 651nm/667nm AF680: 679nm/702nm AF750: 749nm/775nm
Calculated MW	Refer to figures
Formulation	0.01M Sodium Phosphate, 0.25M NaCl, pH 7.6, 5mg/ml Bovine Serum Albumin, 0.02% Sodium Azide
Storage	Store at 4°C in dark for 6 months

Application Details

Suggested Dilution:

AF350 conjugated: most applications: 1: 50 - 1: 250

AF405 conjugated: most applications: 1: 50 - 1: 250

AF488 conjugated: most applications: 1: 50 - 1: 250

AF555 conjugated: most applications: 1: 50 - 1: 250

AF594 conjugated: most applications: 1: 50 - 1: 250

AF647 conjugated: most applications: 1: 50 - 1: 250

AF680 conjugated: most applications: 1: 50 - 1: 250

AF750 conjugated: most applications: 1: 50 - 1: 250

Biotin conjugated: working with enzyme-conjugated streptavidin, most applications: 1: 50 - 1: 1,000

Background

This gene, a Kirsten ras oncogene homolog from the mammalian ras gene family, encodes a protein that is a member of the small GTPase superfamily. A single amino acid substitution is responsible for an activating mutation. The transforming protein that results is implicated in various malignancies, including lung adenocarcinoma, mucinous adenoma, ductal carcinoma of the pancreas and colorectal carcinoma. Alternative splicing leads to variants encoding two isoforms that differ in the C-terminal region.

Note: This product is for in vitro research use only